Drug Search Results
More Filters [+]

Lixisenatide

Alternative Names: lixisenatide, ave0010, adlyxin, soliqua 100/33
Latest Update: 2024-07-24
Latest Update Note: News Article

Product Description

Lixisenatide is a 44-amino acid peptide. Like exenatide, it is based on exendin-4 with a modification at the C-terminus—a deletion of a proline residue and the addition of six lysine residues.15 It is amidated at the C-terminal amino acid (position 44) (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642155/)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Paresis | Gastroparesis | Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes

Known Adverse Events: Dizziness | Headache | Hypoglycemia | Diarrhea

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lixisenatide

Countries in Clinic: China, France, Hong Kong, Korea, Malaysia, South Korea, Taiwan

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Type 2 Diabetes

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LixiPark

P2

Completed

Parkinson's Disease

2021-04-15

Lixilan-O-AP

P3

Completed

Type 2 Diabetes

2021-03-01

78%

CTR20181388

P3

Completed

Type 2 Diabetes

2021-03-01

Recent News Events